BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
BioNTech SENASDAQ: BNTX
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares grows in line with its trailing trend
Q2 FY2026 weighted avg shares of 253.33M shares rose 4.8% year over year, ahead of the +3.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.
Context
- Weighted avg shares increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4.8% holds above the trailing-twelve-month pace of +3.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 241.7M EUR
- Year-over-year change
- +0.5%
- 4-year CAGR
- -0.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.7M | +0.5% |
| FY2024 | 2024-12-31 | 240.4M | -0.1% |
| FY2023 | 2023-12-31 | 240.6M | -1.1% |
| FY2022 | 2022-12-31 | 243.3M | -0.3% |
| FY2021 | 2021-12-31 | 244M | — |
Weighted Avg Shares vs competitors
How BNTX compares with its peers on the latest reported figures
- BNTX's LTM Jun 2026 weighted avg shares of 247.64M shares is the 4th highest of the 11 companies compared; the peer median is 134.22M shares.
- Its year-over-year change of +3.0% is the 6th highest of 10, against a peer median of +4.2%.
- Over three fiscal years its annual growth of -0.2% compares with a peer median of +2.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 1.03B | +20.6% | +32.0% | |
| LTM Jun 2026 | 614.84M | — | -1.7% | |
| LTM Sep 2026 | 432.9M | +30.6% | +30.9% | |
| LTM Jun 2026 | 247.64M | +3.0% | -0.2% | |
| LTM Jun 2026 | 198.21M | +2.5% | -4.2% | |
| LTM Sep 2026 | 142.49M | -2.4% | +2.1% | |
| LTM Mar 2026 | 125.95M | +14.7% | +22.1% | |
| LTM Mar 2026 | 93.98M | +4.2% | +2.6% | |
| LTM Jun 2026 | 74.94M | +5.1% | +7.6% | |
| LTM Mar 2026 | 63.24M | +0.8% | +0.9% | |
| LTM Mar 2026 | 50.45M | +0.8% | +3.3% | |
| Peer median (excluding BNTX) | 134.22M | +4.2% | +2.9% | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.98B | 17.31B | 3.82B | 2.75B | 2.76B |
| Cost of Revenue | 2.91B | 3B | 599.8M | 541.3M | 616.47M |
| Gross Profit | 16.07B | 14.32B | 3.22B | 2.21B | 2.14B |
| Gross Margin | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| Research & Development | 949.2M | 1.54B | 1.78B | 2.25B | 2.02B |
| Selling, General & Admin | 327.2M | 541.2M | 557.7M | 599M | 698.2M |
| Operating Expenses | 781.4M | 1.67B | 2.53B | 3.52B | 2.76B |
| Depreciation & Amortization | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
| EBITDA | 15B | 13.1B | 1.38B | (367.1M) | (628M) |
| EBITDA Margin | 79.1% | 75.7% | 36.1% | -13.3% | -22.8% |
| Operating Income | 15.28B | 12.64B | 690.4M | (1.31B) | (623.87M) |
| Operating Margin | 80.5% | 73.0% | 18.1% | -47.8% | -22.6% |
| Interest Income | 1.56M | 47.37M | 351.31M | 0 | 252.24M |
| Interest Expense | 5.63M | 15.82M | 7.76M | 13.16M | 13.64M |
| Other Income / Expenses | (237.4M) | 311.4M | 495.7M | 636.6M | (385.46M) |
| Income Before Tax | 15.05B | 12.95B | 1.19B | (677.7M) | (1.01B) |
| Pre-Tax Margin | 79.3% | 74.8% | 31.1% | -24.6% | -36.6% |
| Income Tax Expense | 4.75B | 3.52B | 255.8M | (12.4M) | 81.93M |
| Net Income | 10.29B | 9.43B | 930.3M | (665.3M) | (1.09B) |
| Net Margin | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| EPS (Basic) | 43.87 | 38.08 | 3.87 | (2.77) | (4.51) |
| EPS (Diluted) | 41.21 | 37.09 | 3.83 | (2.77) | (4.51) |
| Weighted Avg Shares | 244M | 243.3M | 240.6M | 240.4M | 241.7M |
| Weighted Avg Shares (Diluted) | 259.7M | 249.8M | 242.7M | 240.4M | 241.7M |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.